Armen Yuri Gasparyan

Publications

• 4.41

  Impact points

  Cardiovascular risk and inflammation: pathophysiological mechanisms, drug design, and targets.

  Armen Yuri Gasparyan

  Current pharmaceutical design. 02/2012; 18(11):1447-9.
• 4.41

  Impact points

  Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research.

  Armen Yuri Gasparyan, Lilit Ayvazyan, Giuseppe Cocco, George D Kitas

  Current pharmaceutical design. 02/2012; 18(11):1543-55.

  Clinical manifestations of most rheumatic diseases have changed over the past few decades, largely due to advances in therapies targeting autoimmune and (auto)inflammatory pathways. Improvements in the management of rheumatic diseases have also now brought to the fore the issue of comorbidities. It ... [more] Clinical manifestations of most rheumatic diseases have changed over the past few decades, largely due to advances in therapies targeting autoimmune and (auto)inflammatory pathways. Improvements in the management of rheumatic diseases have also now brought to the fore the issue of comorbidities. It has become evident that the burden of cardiovascular morbidity and mortality is increased in rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and the spondyloarthropathies, amongst other conditions. As a result, efforts have switched toward investigating the effects of conventional antirheumatic and new biologic agents on inflammationinduced atherothrombosis. Evidence is accumulating suggesting a beneficial cardiovascular profile of some antirheumatic drugs, such as methotrexate and hydroxychloroquine, but it also indicates the possibility of a variety of adverse events developing in the short- and long-term. The aim of this review is to highlight cardiovascular adverse effects of the drugs widely used in the treatment of rheumatic diseases. The literature search was performed through PubMed, the Cochrane Library, Scopus, and Web of Science databases using the following terms: "antirheumatic drugs", "inflammation", "rheumatic diseases", "cardiovascular diseases", "adverse events", "toxicity", "drug design", and "drug interactions". Adverse events ranging from infusion-related hypertension and myocardial ischemia, to restrictive cardiomyopathy and congestive heart failure have been reported in large trials and case series on most antirheumatic drugs. Clinicians should be alert of the wide variety of cardiovascular adverse effects of individual antirheumatic drugs, and should carefully monitor blood pressure and markers of inflammation, thrombosis, myocardial ischemia, electrolytes, and lipid disturbances while administering these drugs. Future prospective studies should specifically investigate the cardiovascular safety of most antirheumatic drugs as part of mono- or combination therapy in relation to different dosage regimens, duration of therapy, age, and gender.
• 1.49

  Impact points

  Cardiac complications in rheumatoid arthritis in the absence of occlusive coronary pathology.

  Armen Yuri Gasparyan, Giuseppe Cocco, Stefano Pandolfi

  Rheumatology international. 02/2012; 32(2):461-4.

  Cardiovascular disease is the leading cause of premature mortality in patients with rheumatoid arthritis (RA). Pathophysiology of rheumatoid cardiovascular phenomenon is not fully understood, but systemic inflammation is thought to play a crucial role in the endothelial damage and accelerated course... [more] Cardiovascular disease is the leading cause of premature mortality in patients with rheumatoid arthritis (RA). Pathophysiology of rheumatoid cardiovascular phenomenon is not fully understood, but systemic inflammation is thought to play a crucial role in the endothelial damage and accelerated course of atherosclerotic disease. Rheumatoid inflammation can also cause coronary pathology and heart failure. We present a case of transient cardiomyopathy in RA in the absence of occlusive coronary pathology, which mimics acute coronary syndrome.
• 1.49

  Impact points

  Diversity, value and limitations of the journal impact factor and alternative metrics.

  Lutz Bornmann, Werner Marx, Armen Yuri Gasparyan, George D Kitas

  Rheumatology international. 12/2011;

  The highly popular journal impact factor (JIF) is an average measure of citations within 1 year after the publication of a journal as a whole within the two preceding years. It is widely used as a proxy of a journal's quality and scientific prestige. This article discusses misuses of JIF to asse... [more] The highly popular journal impact factor (JIF) is an average measure of citations within 1 year after the publication of a journal as a whole within the two preceding years. It is widely used as a proxy of a journal's quality and scientific prestige. This article discusses misuses of JIF to assess impact of separate journal articles and the effect of several manuscript versions on JIF. It also presents some newer alternative journal metrics such as SCImago Journal Rank and the h-index and analyses examples of their application in several subject categories.
• 1.37

  Impact points

  Familiarizing with science editors' associations.

  Armen Yuri Gasparyan

  Croatian medical journal. 12/2011; 52(6):735-9.

  The number of science editors' associations is growing to resolve a variety of professional problems. The main objective of the associations is to educate their members by facilitating dissemination of information, publishing scholarly journals, books, networking of experts, and regular meetings... [more] The number of science editors' associations is growing to resolve a variety of professional problems. The main objective of the associations is to educate their members by facilitating dissemination of information, publishing scholarly journals, books, networking of experts, and regular meetings. There are many science editing associations - general and specialized, traditional, and new. The article presents activities of some of these associations, which include upholding standards of science writing, editing, indexing, research reporting, peer review, editorial independence, and other editorial policies.

  Download
• 1.49

  Impact points

  Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors.

  Armen Yuri Gasparyan, Lilit Ayvazyan, Heather Blackmore, George D Kitas

  Rheumatology international. 07/2011; 31(11):1409-17.

  Review articles comprehensively covering a specific topic are crucial for successful research and academic projects. Most editors consider review articles for special and regular issues of journals. Writing a review requires deep knowledge and understanding of a field. The aim of this review is to a... [more] Review articles comprehensively covering a specific topic are crucial for successful research and academic projects. Most editors consider review articles for special and regular issues of journals. Writing a review requires deep knowledge and understanding of a field. The aim of this review is to analyze the main steps in writing a narrative biomedical review and to consider points that may increase the chances of success. We performed a comprehensive search through MEDLINE, EMBASE, Scopus, and Web of Science using the following keywords: review of the literature, narrative review, title, abstract, authorship, ethics, peer review, research methods, medical writing, scientific writing, and writing standards. Opinions expressed in the review are also based on personal experience as authors, peer reviewers, and editors.
• 1.37

  Impact points

  Biomedical journal editing: elements of success.

  Armen Yuri Gasparyan, Lilit Ayvazyan, George D Kitas

  Croatian medical journal. 06/2011; 52(3):423-8.

  Download
• 2.24

  Impact points

  Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis.

  A Sandoo, V F Panoulas, T E Toms, J P Smith, A Stavropoulos-Kalinoglou, G S Metsios, A Y Gasparyan, D Carroll, J J C S Veldhuijzen van Zanten, G D Kitas

  Journal of human hypertension. 04/2011; 25(11):699-702.
• 2.97

  Impact points

  Platelet function and antiplatelet therapy in cardiovascular disease: implications of genetic polymorphisms.

  Jayashree Shanker, Armen Yuri Gasparyan, George D Kitas, Vijay V Kakkar

  Current vascular pharmacology. 02/2011; 9(4):479-89.

  Platelets play a crucial role in thrombosis, inflammation, immunity and atherogenesis. Antiplatelet agents are widely used in patients with acute coronary syndrome and other cardiovascular disorders. Aspirin and clopidogrel are the most commonly prescribed antiplatelet agents, with a relatively safe... [more] Platelets play a crucial role in thrombosis, inflammation, immunity and atherogenesis. Antiplatelet agents are widely used in patients with acute coronary syndrome and other cardiovascular disorders. Aspirin and clopidogrel are the most commonly prescribed antiplatelet agents, with a relatively safe profile and efficiency in a variety of clinical conditions. Numerous prospective studies have revealed variability of antiplatelet efficacy. The so called "antiplatelet resistance" prompted a search for mechanisms implicated in poor responsiveness to aspirin and clopidogrel therapy. In this regard, genetic polymorphisms in the platelet receptor genes attracted considerable interest. Specific genetic variants in platelet receptors such as the P2Y12, glycoprotein (GP) IIb/IIIa, GPIa/IIa, GPIb/IX/V and the cytochrome P450 (CYP) family of genes are associated with variable response to antiplatelet therapy and cardiovascular events. Genetic polymorphisms and haplotypes that comprehensively capture the genetic information encoded within the platelet receptor genes can, to some extent, predict response to the antiplatelet drug better than any single genotype. Genotyping for multiple receptor variants in patients on antiplatelet therapy, complemented by standardized quantification of platelet function, can provide useful information for future drug design studies and possibly for personalized antiplatelet therapy and prevention of thrombotic events. Additional information is, however, needed to evaluate the cost-effectiveness of complex genetic and platelet function testing.

• European Science Editing in a time of change

  Armen Yuri Gasparyan

  European Science Editing. 01/2011; 37(2):30.

  European Science Editing, a scientific and educational organ of the European Association of Science Editors, has developed from a simple newsletter to an internationally recognized journal covering science writing, editing, and publishing. Following the digital trend, changes are being introduced to... [more] European Science Editing, a scientific and educational organ of the European Association of Science Editors, has developed from a simple newsletter to an internationally recognized journal covering science writing, editing, and publishing. Following the digital trend, changes are being introduced to facilitate online accessibility and retrievability, to make the information within the journal more readily available to a global audience.

  Download

• Combining science editors’ and clinicians’ efforts to advance writing and editing skills

  Armen Yuri Gasparyan

  European Science Editing. 01/2011; 37:102-103.

  Download
• 4.41

  Impact points

  Mean platelet volume: a link between thrombosis and inflammation?

  Armen Yuri Gasparyan, Lilit Ayvazyan, Dimitri P Mikhailidis, George D Kitas

  Current pharmaceutical design. 01/2011; 17(1):47-58.

  Platelet activation is a link in the pathophysiology of diseases prone to thrombosis and inflammation. Numerous platelet markers, including mean platelet volume (MPV), have been investigated in connection with both thrombosis and inflammation. This review considers MPV as a prognostic and therapeuti... [more] Platelet activation is a link in the pathophysiology of diseases prone to thrombosis and inflammation. Numerous platelet markers, including mean platelet volume (MPV), have been investigated in connection with both thrombosis and inflammation. This review considers MPV as a prognostic and therapeutic marker as well as the factors influencing its measurement. Established cardiovascular risk factors, such as smoking, hypertension, dyslipidemia, and diabetes, can influence MPV, depending on confounding factors. Low-grade inflammation is one such factor. Evidence, particularly derived from prospective studies and a meta-analysis, suggest a correlation between an increase in MPV and the risk of thrombosis. High MPV associates with a variety of established risk factors, cardio- and cerebrovascular disorders, and low-grade inflammatory conditions prone to arterial and venous thromboses. High-grade inflammatory diseases, such as active rheumatoid arthritis or attacks of familial Mediterranean fever, present with low levels of MPV, which reverse in the course of anti-inflammatory therapy. Lifestyle modification, antihypertensive, lipid lowering and diet therapies can also affect MPV values, but these effects need to be investigated in large prospective studies with thrombotic endpoints.

• Get indexed and cited, or perish

  Gasparyan AY

  European Science Editing. 01/2011; 37:66.

  Download
• 1.49

  Impact points

  Diversity, value and limitations of the journal impact factor and alternative metrics.

  Bornmann L, Marx W, Gasparyan AY, Kitas GD

  Rheumatology International. 01/2011;

  The highly popular journal impact factor (JIF) is an average measure of citations within 1 year after the publication of a journal as a whole within the two preceding years. It is widely used as a proxy of a journal's quality and scientific prestige. This article discusses misuses of JIF to asse... [more] The highly popular journal impact factor (JIF) is an average measure of citations within 1 year after the publication of a journal as a whole within the two preceding years. It is widely used as a proxy of a journal's quality and scientific prestige. This article discusses misuses of JIF to assess impact of separate journal articles and the effect of several manuscript versions on JIF. It also presents some newer alternative journal metrics such as SCImago Journal Rank and the h-index and analyses examples of their application in several subject categories.

• Platelets in inflammation and thrombosis.

  Armen Yuri Gasparyan

  Inflammation & allergy drug targets. 12/2010; 9(5):319-21.

  Download
• 0.38

  Impact points

  Further expanding possibilities of successful stem cell transplantation in coronary artery disease/an alternative approach of stem cell delivery to myocardium: combined usage of antegrade coronary arterial infusion and retrograde venous obstruction.

  Fuat Büyükbayrak, Oğuzhan Karatepe, Mete Alp, Armen Yuri Gasparyan

  Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology. 06/2010; 10(3):292-3.
• 1.49

  Impact points

  Mean platelet volume in patients with rheumatoid arthritis: the effect of anti-TNF-α therapy.

  Armen Yuri Gasparyan, Aamer Sandoo, Antonios Stavropoulos-Kalinoglou, George D Kitas

  Rheumatology international. 06/2010; 30(8):1125-9.

  A number of mediators are involved in the inflammatory processes that affect joints and vascular wall of patients with rheumatoid arthritis (RA). Tumour necrosis factor alpha (TNFa) is one such mediator, and it is widely regarded as an important target for anti-rheumatic treatment. Most recent studi... [more] A number of mediators are involved in the inflammatory processes that affect joints and vascular wall of patients with rheumatoid arthritis (RA). Tumour necrosis factor alpha (TNFa) is one such mediator, and it is widely regarded as an important target for anti-rheumatic treatment. Most recent studies show that anti-TNFa medication suppresses inflammation and reduces overall activity of RA. The aim of the current study was to investigate changes of mean platelet volume (MPV) in response to the 3-month anti-TNFa therapy in RA. Twenty-one RA patients without established cardiovascular disease were recruited for anti-TNFa therapy and underwent thorough clinical and laboratory evaluation at baseline, 2 weeks, and 12 weeks. Anti-TNFa therapy resulted in a significant (p = 0.01) increase in MPV over the duration of the study (7.7 +/- 0.9, 7.8 +/- 1.1, and 8.4 +/- 1.1 fL at baseline, 2 weeks, and 12 weeks, respectively). The results of the study expand perspectives of the use of MPV in conditions associated with high-grade inflammation, particularly RA, for monitoring anti-inflammatory treatment. More prospective studies with large numbers of patients are warranted to ascertain associations of high and low values of MPV with diverse markers of inflammation and vascular pathology.
• 1.49

  Impact points

  Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications.

  Armen Yuri Gasparyan, Antonios Stavropoulos-Kalinoglou, Dimitri P Mikhailidis, Karen M J Douglas, George D Kitas

  Rheumatology international. 04/2010; 31(2):153-64.

  Patients with rheumatoid arthritis (RA) are at high risk of cardiovascular events. Platelet biomarkers are involved in inflammation, atherosclerosis and thrombosis. Cardiovascular and RA-associated factors can alter the structure and function of platelets, starting from megakaryocytopoiesis. Reactiv... [more] Patients with rheumatoid arthritis (RA) are at high risk of cardiovascular events. Platelet biomarkers are involved in inflammation, atherosclerosis and thrombosis. Cardiovascular and RA-associated factors can alter the structure and function of platelets, starting from megakaryocytopoiesis. Reactive megakaryocytopoiesis increases circulating platelets count and triggers hyperactivity. Hyperactive platelets target synovial membranes with subsequent local rheumatoid inflammation. Hyperactive platelets interact with other cells, and target the vascular wall. Accumulating evidence suggests that disease modifying anti-rheumatic drugs (DMARD) decrease platelet activity.

• Thoughts on impact factors and editing of medical journals.

  Armen Yuri Gasparyan

  Inflammation & allergy drug targets. 03/2010; 9(1):2-5.

  Download

• Inflammation, thrombosis and vascular biology: translating ideas into cardiovascular research and therapy.

  Armen Yuri Gasparyan

  The open cardiovascular medicine journal. 01/2010; 4:20-2.

  Download